-
1
-
-
44649187924
-
Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled Trials
-
DOI 10.1016/j.cgh.2008.03.014, PII S1542356508002917
-
Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF,. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008; 6: 644-53. (Pubitemid 351783447)
-
(2008)
Clinical Gastroenterology and Hepatology
, vol.6
, Issue.6
, pp. 644-653
-
-
Peyrin-Biroulet, L.1
Deltenre, P.2
De Suray, N.3
Branche, J.4
Sandborn, W.J.5
Colombel, J.6
-
2
-
-
79958228566
-
Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease
-
Peyrin-Biroulet L, Oussalah A, Williet N, Pillot C, Bresler L, Bigard M-A,. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. Gut 2011; 60: 930-6.
-
(2011)
Gut
, vol.60
, pp. 930-936
-
-
Peyrin-Biroulet, L.1
Oussalah, A.2
Williet, N.3
Pillot, C.4
Bresler, L.5
Bigard, M.-A.6
-
3
-
-
78649713662
-
Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy
-
Rahier J-F, Buche S, Peyrin-Biroulet L, et al,. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol 2010; 8: 1048-55.
-
(2010)
Clin Gastroenterol Hepatol
, vol.8
, pp. 1048-1055
-
-
Rahier, J.-F.1
Buche, S.2
Peyrin-Biroulet, L.3
-
4
-
-
63849251824
-
Long-term safety of infliximab for the treatment of inflammatory bowel disease: A single-centre cohort study
-
Fidder H, Schnitzler F, Ferrante M, et al,. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009; 58: 501-8.
-
(2009)
Gut
, vol.58
, pp. 501-508
-
-
Fidder, H.1
Schnitzler, F.2
Ferrante, M.3
-
5
-
-
58849160468
-
Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: Results from the British Society for Rheumatology Biologics Register
-
Harrison MJ, Dixon WG, Watson KD, et al,. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009; 68: 209-15.
-
(2009)
Ann Rheum Dis
, vol.68
, pp. 209-215
-
-
Harrison, M.J.1
Dixon, W.G.2
Watson, K.D.3
-
6
-
-
81355151359
-
Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: A new series and a review of 120 cases from the literature
-
Cullen G, Kroshinsky D, Cheifetz AS, Korzenik JR,. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther 2011; 34: 1318-27.
-
(2011)
Aliment Pharmacol Ther
, vol.34
, pp. 1318-1327
-
-
Cullen, G.1
Kroshinsky, D.2
Cheifetz, A.S.3
Korzenik, J.R.4
-
7
-
-
84856302095
-
Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: Results of an open-label, active-controlled, randomized trial (RESTORE1)
-
Barker J, Hoffmann M, Wozel G, et al,. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol 2011; 165: 1109-17.
-
(2011)
Br J Dermatol
, vol.165
, pp. 1109-1117
-
-
Barker, J.1
Hoffmann, M.2
Wozel, G.3
-
8
-
-
68949149916
-
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents
-
Menter A, Korman NJ, Elmets CA, et al,. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009; 61: 451-85.
-
(2009)
J Am Acad Dermatol
, vol.61
, pp. 451-485
-
-
Menter, A.1
Korman, N.J.2
Elmets, C.A.3
-
9
-
-
84859891279
-
Incidence of and impact of medications on colectomy in newly diagnosed ulcerative colitis in the era of biologics
-
[Epub ahead of print]
-
Williet N, Pillot C, Oussalah A, et al,. Incidence of and impact of medications on colectomy in newly diagnosed ulcerative colitis in the era of biologics. Inflamm Bowel Dis 2011 [Epub ahead of print].
-
(2011)
Inflamm Bowel Dis
-
-
Williet, N.1
Pillot, C.2
Oussalah, A.3
-
10
-
-
84858708450
-
Urinary tract infections in hospitalized inflammatory bowel disease patients: A 10-year experience
-
Peyrin-Biroulet L, Pillot C, Oussalah A, et al,. Urinary tract infections in hospitalized inflammatory bowel disease patients: a 10-year experience. Inflamm Bowel Dis 2012; 18: 697-702.
-
(2012)
Inflamm Bowel Dis
, vol.18
, pp. 697-702
-
-
Peyrin-Biroulet, L.1
Pillot, C.2
Oussalah, A.3
-
11
-
-
84859917921
-
Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: The Mayo Clinic experience, 1998 to 2010
-
[Epub ahead of print]
-
Shmidt E, Wetter DA, Ferguson SB, Pittelkow MR,. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010. J Am Acad Dermatol 2011 [Epub ahead of print].
-
(2011)
J Am Acad Dermatol
-
-
Shmidt, E.1
Wetter, D.A.2
Ferguson, S.B.3
Pittelkow, M.R.4
-
12
-
-
0028899859
-
Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators
-
Feagan BG, Rochon J, Fedorak RN, et al,. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995; 332: 292-7.
-
(1995)
N Engl J Med
, vol.332
, pp. 292-297
-
-
Feagan, B.G.1
Rochon, J.2
Fedorak, R.N.3
-
13
-
-
0034214336
-
A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease
-
DOI 10.1056/NEJM200006013422202
-
Feagan BG, Fedorak RN, Irvine EJ, et al,. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000; 342: 1627-32. (Pubitemid 30341531)
-
(2000)
New England Journal of Medicine
, vol.342
, Issue.22
, pp. 1627-1632
-
-
Feagan, B.G.1
Fedorak, R.N.2
Irvine, E.J.3
Wild, G.4
Sutherland, L.5
Steinhart, A.H.6
Greenberg, G.R.7
Koval, J.8
Wong, C.J.9
Hopkins, M.10
Hanauer, S.B.11
Mcdonald, J.W.D.12
-
14
-
-
39049143819
-
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)
-
DOI 10.1111/j.1365-2133.2007.08315.x
-
Saurat J-H, Stingl G, Dubertret L, et al,. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558-66. (Pubitemid 351239154)
-
(2008)
British Journal of Dermatology
, vol.158
, Issue.3
, pp. 558-566
-
-
Saurat, J.-H.1
Stingl, G.2
Dubertret, L.3
Papp, K.4
Langley, R.G.5
Ortonne, J.-P.6
Unnebrink, K.7
Kaul, M.8
Camez, A.9
-
15
-
-
63849102069
-
Review article: Anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease
-
Fiorino G, Allez M, Malesci A, Danese S,. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2009; 29: 921-7.
-
(2009)
Aliment Pharmacol Ther
, vol.29
, pp. 921-927
-
-
Fiorino, G.1
Allez, M.2
Malesci, A.3
Danese, S.4
-
16
-
-
14744276518
-
Cross-regulation of TNF and IFN-α in autoimmune diseases
-
DOI 10.1073/pnas.0408506102
-
Palucka AK, Blanck J-P, Bennett L, Pascual V, Banchereau J,. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci U.S.A. 2005; 102: 3372-7. (Pubitemid 40328052)
-
(2005)
Proceedings of the National Academy of Sciences of the United States of America
, vol.102
, Issue.9
, pp. 3372-3377
-
-
Palucka, A.K.1
Blanck, J.-P.2
Bennett, L.3
Pascual, V.4
Banchereau, J.5
-
17
-
-
22344438901
-
Plasmacytoid predendritic cells initiate psoriasis through interferon-α production
-
DOI 10.1084/jem.20050500
-
Nestle FO, Conrad C, Tun-Kyi A, et al,. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005; 202: 135-43. (Pubitemid 41002916)
-
(2005)
Journal of Experimental Medicine
, vol.202
, Issue.1
, pp. 135-143
-
-
Nestle, F.O.1
Conrad, C.2
Tun-Kyi, A.3
Homey, B.4
Gombert, M.5
Boyman, O.6
Burg, G.7
Liu, Y.-J.8
Gilliet, M.9
|